Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (5096)	12/10/2001 10:31:34 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

IJ, <MRK> It's hard to make any significant impact on a company that size (over $150 billion market cap) other than by munching another pharma like SGP. Something like SEPR, with its robust pipeline for a non-pharma, would make barely a ripple over the next few years. I suppose that some of the mini-pharma like ELN, FRX and SRA might have some impact. Of these FRX probably has the best pipeline (unless the ELN Alzheimer's vaccine is for real). Of course none of these are cheap compared with MRK, and all would be dilutive to earnings. BMY or SGP would be roughly earnings-neutral, assuming not much premium. Bottom line is I think they'll just try to tough it out for a year or two. They are certainly not alone in facing patent expiration hell - BMY, LLY, SGP and AZN are all in the same boat. Peter P.S. The munch thread is the place where these discussions are usually conducted: Subject 24574